TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 9594209

Group type: EXPERIMENTAL
Intervention: Predilutional HDF
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Postdilutional HDF
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Hemofiltration (HF)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Bicarbonate HD
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Predilutional HF
Number of subjects: 40
Study: 8934963

Group type: EXPERIMENTAL
Intervention: Triazolam (0.375 or 0.50 mg)
Number of subjects: 31

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 31
Study: 3355641

Group type: EXPERIMENTAL
Intervention: Arthroscopic reconstruction
Number of subjects: 20

Group type: COMPARATOR
Intervention: Miniarthrotomy reconstruction
Number of subjects: 20
Study: 31161583

Group type: EXPERIMENTAL
Intervention: Internal medicine residents and attending physicians
Number of subjects: 67

Group type: EXPERIMENTAL
Intervention: Internal medicine residents
Number of subjects: 67
Study: 30691749

Group type: EXPERIMENTAL
Intervention: Manipulation (M)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Stabilization exercises (S)
Number of subjects: 40
Study: 29096775

Group type: EXPERIMENTAL
Intervention: I‐InTERACT (10 to 14 sessions addressing parenting skills, TBI education, stress, and anger management)
Number of subjects: 113

Group type: EXPERIMENTAL
Intervention: Express (7 online parent skills sessions)
Number of subjects: 113

Group type: COMPARATOR
Intervention: IRC (access to online TBI and parent skills resources)
Number of subjects: 113
Study: 25465108

Group type: EXPERIMENTAL
Intervention: Transdermal glyceryl trinitrate (5 mg per day) for 7 days, started within 48 h of stroke onset
Number of subjects: 4011

Group type: EXPERIMENTAL
Intervention: Continue antihypertensive drugs
Number of subjects: 4011

Group type: COMPARATOR
Intervention: No glyceryl trinitrate (control group)
Number of subjects: 4011

Group type: COMPARATOR
Intervention: Stop antihypertensive drugs
Number of subjects: 4011

Group type: EXPERIMENTAL
Intervention: Transdermal glyceryl trinitrate
Number of subjects: 4011
Study: 23245443

Group type: EXPERIMENTAL
Intervention: Surgical ventricular restoration (SVR) in STICH patients (SSVR)
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: Surgical ventricular restoration (SVR) in non-STICH patients (NSSVR)
Number of subjects: 21
Study: 21597880

Group type: EXPERIMENTAL
Intervention: Attention training program
Number of subjects: 32

Group type: COMPARATOR
Intervention: Visual perception training
Number of subjects: 32
Study: 18165592

Group type: EXPERIMENTAL
Intervention: Morphine plus ketamine (1.5 mg each) - Group MK
Number of subjects: 352

Group type: COMPARATOR
Intervention: Morphine alone (1.5 mg) - Group M
Number of subjects: 352
Study: 17314337

Group type: EXPERIMENTAL
Intervention: Combination regimen of salmeterol (50 microg) plus fluticasone propionate (500 microg) twice daily
Number of subjects: 6112

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 6112

Group type: COMPARATOR
Intervention: Salmeterol alone
Number of subjects: 6112

Group type: COMPARATOR
Intervention: Fluticasone propionate alone
Number of subjects: 6112

Group type: EXPERIMENTAL
Intervention: Combination regimen of salmeterol plus fluticasone
Number of subjects: 6112

Group type: COMPARATOR
Intervention: Fluticasone propionate (in combination or alone)
Number of subjects: 6112
Study: 15119869

Group type: EXPERIMENTAL
Intervention: Mandibular two-implant overdenture
Number of subjects: 60

Group type: COMPARATOR
Intervention: Conventional denture
Number of subjects: 60
Study: 11731731

Group type: EXPERIMENTAL
Intervention: Burst-suppression anesthesia (BSA)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Sham-burst-suppression anesthesia (sham-BSA)
Number of subjects: 20
Study: 9457400

Group type: EXPERIMENTAL
Intervention: High-dose intravenous rIL-2 (720,000 IU/kg)
Number of subjects: 348

Group type: COMPARATOR
Intervention: Low-dose intravenous rIL-2 (72,000 IU/kg)
Number of subjects: 348

Group type: COMPARATOR
Intervention: Subcutaneous outpatient rIL-2 (week 1: 250,000 IU/kg/day for 5 of 7 days; weeks 2-6: 125,000 IU/kg/day for 5 of 7 days)
Number of subjects: 348
Study: 8032699

Group type: EXPERIMENTAL
Intervention: 5‐HT3 receptor antagonist (5‐HT3 RA)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Ondansetron plus dexamethasone
Number of subjects: 0

Group type: COMPARATOR
Intervention: Ondansetron alone
Number of subjects: 0
Study: 3583492

Group type: EXPERIMENTAL
Intervention: Sulglycotide (400 mg thrice daily)
Number of subjects: 16

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 16
Study: 31003653

Group type: EXPERIMENTAL
Intervention: Non-supervised breathing exercise regimen
Number of subjects: 51

Group type: EXPERIMENTAL
Intervention: Supervised breathing exercise regimen
Number of subjects: 51

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 51
Study: 28666096

Group type: EXPERIMENTAL
Intervention: Dexamethasone (4 mg)
Number of subjects: 65

Group type: EXPERIMENTAL
Intervention: Methylprednisolone (40 mg)
Number of subjects: 65

Group type: COMPARATOR
Intervention: Placebo (control)
Number of subjects: 65
Study: 26596730

Group type: EXPERIMENTAL
Intervention: Riluzole (50 mg twice daily for 1 month)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Placebo (Vitamin B complex tablets)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Riluzole
Number of subjects: 30

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study: 25411735

Group type: EXPERIMENTAL
Intervention: Double layer of collagen membrane (test)
Number of subjects: 36

Group type: COMPARATOR
Intervention: Flowable polylactide polymer (control)
Number of subjects: 36
Study: 21960180

Group type: EXPERIMENTAL
Intervention: Depot naltrexone (XRNT)
Number of subjects: 15
Study: 19930332

Group type: EXPERIMENTAL
Intervention: Trospium XR 60 mg
Number of subjects: 1165

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1165
Study: 17342558

Group type: EXPERIMENTAL
Intervention: General anesthesia plus intraoperative intercostals neural blockade using 0.5% bupivacaine‐adrenaline
Number of subjects: 61

Group type: COMPARATOR
Intervention: Only general anesthesia (control group)
Number of subjects: 61
Study: 15313081

Group type: EXPERIMENTAL
Intervention: Practice-based intervention
Number of subjects: 200

Group type: EXPERIMENTAL
Intervention: Patient-based intervention
Number of subjects: 200

Group type: EXPERIMENTAL
Intervention: Both interventions combined
Number of subjects: 200

Group type: COMPARATOR
Intervention: Control
Number of subjects: 200
Study: 11468201

Group type: EXPERIMENTAL
Intervention: Eptifibatide (180-microgram/kg bolus followed by 2 microgram/kg per minute infusion) with a second bolus of 90 microgram/kg
Number of subjects: 39

Group type: EXPERIMENTAL
Intervention: Eptifibatide (250-microgram/kg bolus followed by 3 microgram/kg per minute infusion) with a second bolus of 125 microgram/kg
Number of subjects: 39

Group type: COMPARATOR
Intervention: Single-bolus regimens of eptifibatide
Number of subjects: 39

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 39
Study: 9684070

Group type: EXPERIMENTAL
Intervention: Predicted corneal acuity (PCA) in normal eyes
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Predicted corneal acuity (PCA) in eyes with corneal abnormalities
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Predicted corneal acuity (PCA) in patients with high irregular astigmatism
Number of subjects: 20
Study: 8067786

Group type: EXPERIMENTAL
Intervention: 4 IU/m2/day of recombinant human growth hormone (rhGH)
Number of subjects: 38

Group type: COMPARATOR
Intervention: 2 IU/m2/day of recombinant human growth hormone (rhGH)
Number of subjects: 38

Group type: EXPERIMENTAL
Intervention: Both doses of rhGH
Number of subjects: 38

Group type: EXPERIMENTAL
Intervention: 3 years of rhGH treatment
Number of subjects: 38

Group type: EXPERIMENTAL
Intervention: 1 year of rhGH treatment
Number of subjects: 38
Study: 3065157

Group type: EXPERIMENTAL
Intervention: Maalox TC three tablets at bedtime (81 mmol)
Number of subjects: 251

Group type: EXPERIMENTAL
Intervention: Maalox TC three tablets in the morning plus three tablets at bedtime (bd) (162 mmol)
Number of subjects: 251

Group type: EXPERIMENTAL
Intervention: Cimetidine 400 mg at bedtime
Number of subjects: 251

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 251
Study: 31834058

Group type: EXPERIMENTAL
Intervention: Methylphenidate
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Sertraline
Number of subjects: 0
Study: 29879711

Group type: EXPERIMENTAL
Intervention: Fluoridated water (0.70 mg F/L)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Fluoridated salt (183.7 mg F/kg)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Nonfluoridated water and salt (control group)
Number of subjects: 12
Study: 28426301

Group type: EXPERIMENTAL
Intervention: HOLA en Grupos intervention
Number of subjects: 304
Study: 25810468

Group type: EXPERIMENTAL
Intervention: Gratitude intervention
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Emotion regulation
Number of subjects: 0
Study: 24589049

Group type: EXPERIMENTAL
Intervention: Nurse-initiated evidence-based practice (EBP) study on urinary catheterization
Number of subjects: 0
Study: 21838411

Group type: EXPERIMENTAL
Intervention: Duloxetine 60 mg once daily
Number of subjects: 528

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 528
Study: 19289619

Group type: EXPERIMENTAL
Intervention: Capecitabine plus trastuzumab (6 mg/kg body weight in 3-week cycles)
Number of subjects: 156

Group type: COMPARATOR
Intervention: Capecitabine (2,500 mg/m2 on days 1 through 14)
Number of subjects: 156

Group type: EXPERIMENTAL
Intervention: Capecitabine plus trastuzumab
Number of subjects: 156

Group type: COMPARATOR
Intervention: Capecitabine
Number of subjects: 156
Study: 17546382

Group type: EXPERIMENTAL
Intervention: Junior dentist group
Number of subjects: 164

Group type: COMPARATOR
Intervention: Senior dentist group
Number of subjects: 164
Study: 15326069

Group type: EXPERIMENTAL
Intervention: Dual-chamber ICD with TDI of >=469 ms
Number of subjects: 102

Group type: COMPARATOR
Intervention: Single-chamber ICD with TDI 30 to 60 ms above the slowest documented VT cycle length
Number of subjects: 102
Study: 11092994

Group type: EXPERIMENTAL
Intervention: Trandolapril (2 mg/day, n = 8)
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: Candesartan cilexetil (8 mg/day, n = 8)
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: Verapamil (120 mg/day, n = 8)
Number of subjects: 32

Group type: COMPARATOR
Intervention: Placebo (n = 8)
Number of subjects: 32
Study: 9350384

Group type: EXPERIMENTAL
Intervention: rizatriptan 10 mg
Number of subjects: 417

Group type: EXPERIMENTAL
Intervention: rizatriptan 5 mg
Number of subjects: 417

Group type: EXPERIMENTAL
Intervention: rizatriptan 2.5 mg
Number of subjects: 417

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 417

Group type: EXPERIMENTAL
Intervention: rizatriptan 5 mg and 10 mg
Number of subjects: 417
Study: 8421262

Group type: EXPERIMENTAL
Intervention: Asthma self-management programme (SM)
Number of subjects: 27

Group type: EXPERIMENTAL
Intervention: Asthma self-management programme including relaxation training (SM + R)
Number of subjects: 27

Group type: COMPARATOR
Intervention: Control group (CG) - pharmacological treatment only
Number of subjects: 27
Study: 3533547

Group type: EXPERIMENTAL
Intervention: Metoprolol (100-200 mg daily)
Number of subjects: 34

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 34

Group type: EXPERIMENTAL
Intervention: Metoprolol (after withdrawal)
Number of subjects: 34

Group type: COMPARATOR
Intervention: Placebo (after withdrawal)
Number of subjects: 34
Study: 29871371

Group type: EXPERIMENTAL
Intervention: Subpedicular approach (SP)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Retrodiscal approach (RD)
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Both SP and RD groups
Number of subjects: 50
Study: 27173037

Group type: EXPERIMENTAL
Intervention: BuMA sirolimus-eluting stent (SES)
Number of subjects: 2348

Group type: COMPARATOR
Intervention: Excel sirolimus-eluting stent (SES)
Number of subjects: 2348
Study: 25047927

Group type: EXPERIMENTAL
Intervention: Three-dimensional positioning technique during maxillary repositioning along with an intermediate occlusal splint
Number of subjects: 26

Group type: COMPARATOR
Intervention: Intermediate occlusal splint with internal reference points
Number of subjects: 26
Study: 22517228

Group type: EXPERIMENTAL
Intervention: Bovine-derived collagen (BDC)/ionic silver dressing
Number of subjects: 10

Group type: COMPARATOR
Intervention: Sodium carboxymethylcellulose/1.2% ionic silver (CMC) dressing
Number of subjects: 10
Study: 21284249

Group type: EXPERIMENTAL
Intervention: New Pro‐Argin formula toothpaste (8.0% arginine, 1450 ppm fluoride)
Number of subjects: 121

Group type: EXPERIMENTAL
Intervention: Commercial Pro‐Argin formula toothpaste (8.0% arginine, 1450 ppm fluoride)
Number of subjects: 121

Group type: COMPARATOR
Intervention: Negative control toothpaste (calcium carbonate, 1450 ppm fluoride)
Number of subjects: 121
Study: 19049295

Group type: EXPERIMENTAL
Intervention: Bromfenac sodium ophthalmic solution 0.1%
Number of subjects: 54
Study: 15258610

Group type: EXPERIMENTAL
Intervention: Deep sclerectomy (DS)
Number of subjects: 13

Group type: EXPERIMENTAL
Intervention: Deep sclerectomy with collagen implant (DSCI)
Number of subjects: 13
Study: 12391104

Group type: EXPERIMENTAL
Intervention: Hypoxia (inspired O(2) fraction = 0.10) during Wingate test
Number of subjects: 10

Group type: COMPARATOR
Intervention: Normoxia during Wingate test
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Hypoxia during Wingate test
Number of subjects: 10
Study: 10684957

Group type: EXPERIMENTAL
Intervention: Nursing-led care (NLIU)
Number of subjects: 177

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 177
Study: 8869534

Group type: EXPERIMENTAL
Intervention: Computer-assisted instructional program
Number of subjects: 39

Group type: COMPARATOR
Intervention: Scripted lecture with black-and-white transparencies
Number of subjects: 39
Study: 1347278

Group type: EXPERIMENTAL
Intervention: bismuth subsalicylate, 600 mg three times daily (n = 19)
Number of subjects: 59

Group type: COMPARATOR
Intervention: ranitidine, 300 mg at night (n = 20)
Number of subjects: 59

Group type: EXPERIMENTAL
Intervention: bismuth subsalicylate plus ranitidine (n = 20)
Number of subjects: 59
Study: 3157881

Group type: EXPERIMENTAL
Intervention: 0.4 mg naloxone
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: 2.0 mg naloxone
Number of subjects: 21

Group type: COMPARATOR
Intervention: 0.9% saline (placebo)
Number of subjects: 21
Study: 31368249

Group type: EXPERIMENTAL
Intervention: Obesity intervention 3 days/week (120 min contact per week)
Number of subjects: 243

Group type: EXPERIMENTAL
Intervention: Obesity intervention 5 days/week (200 min contact per week)
Number of subjects: 243

Group type: COMPARATOR
Intervention: Control group (0 days/week)
Number of subjects: 243

Group type: EXPERIMENTAL
Intervention: Obesity intervention 1 day/week (40 min contact per week)
Number of subjects: 243
Study: 29912580

Group type: EXPERIMENTAL
Intervention: Pacifier group (PG)
Number of subjects: 90

Group type: COMPARATOR
Intervention: Control group (CG)
Number of subjects: 90
Study: 27288694

Group type: EXPERIMENTAL
Intervention: Xiao procedure plus spinal cord detethering
Number of subjects: 20

Group type: COMPARATOR
Intervention: Spinal cord detethering only
Number of subjects: 20
Study: 25538330

Group type: EXPERIMENTAL
Intervention: Silodosin 8 mg once daily after dinner for 12 weeks
Number of subjects: 53

Group type: COMPARATOR
Intervention: Tamsulosin 0.4 mg controlled release once daily for 12 weeks
Number of subjects: 53
Study: 22687869

Group type: EXPERIMENTAL
Intervention: Exenatide (group Exe, n = 13)
Number of subjects: 31

Group type: COMPARATOR
Intervention: Glimepiride (group Glm, n = 18)
Number of subjects: 31
Study: 20814040

Group type: EXPERIMENTAL
Intervention: Critical Power (CP) in children (W * kg(‐1))
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Anaerobic Work Capacity (AWC) in children (J * kg(‐1))
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: AWC in children (J * kg(‐1))
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: CP (%MAP) in children
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: CP (%MAP and W * kg(‐1)) and AWC (J * kg(‐1))
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: AWC (J * kg(‐1))
Number of subjects: 0
Study: 17511244

Group type: EXPERIMENTAL
Intervention: Positive mood group
Number of subjects: 51

Group type: EXPERIMENTAL
Intervention: Negative mood group
Number of subjects: 51

Group type: EXPERIMENTAL
Intervention: Neutral mood group
Number of subjects: 51
Study: 16566410

Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study: 11762414

Group type: EXPERIMENTAL
Intervention: Radioimmunotherapy (RIT)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Unlabeled antibody therapy
Number of subjects: 0
Study: 9039930

Group type: EXPERIMENTAL
Intervention: Portal vein flush, no vena caval venting (Group 1)
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Hepatic arterial flush, no vena caval venting (Group 2)
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Portal vein flush with vena caval venting (Group 3)
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Hepatic artery flush with vena caval venting (Group 4)
Number of subjects: 100

Group type: COMPARATOR
Intervention: All groups combined
Number of subjects: 100
Study: 8173919

Group type: EXPERIMENTAL
Intervention: Bupivacaine
Number of subjects: 100

Group type: COMPARATOR
Intervention: Lignocaine
Number of subjects: 100

Group type: COMPARATOR
Intervention: Hyaluronidase and bupivacaine
Number of subjects: 100
Study: 3192867

Group type: EXPERIMENTAL
Intervention: Warm humid air during recovery
Number of subjects: 20

Group type: COMPARATOR
Intervention: Warm dry air during recovery
Number of subjects: 20
Study: 2252531

Group type: EXPERIMENTAL
Intervention: Combined azathioprine and thymostimulin administration
Number of subjects: 45

Group type: COMPARATOR
Intervention: Conventional treatment (Control)
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: Patients in remission (after stopping treatment)
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: Patients receiving azathioprine or thymostimulin alone
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: C-peptide levels in patients with remission
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: Interleukin-2 production in patients in remission
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: Time of beginning immunotherapy after onset of diabetes
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: Age of patients
Number of subjects: 45
Study: 908936

Group type: EXPERIMENTAL
Intervention: Common carotid ligation
Number of subjects: 60

Group type: COMPARATOR
Intervention: Bed rest (conservative treatment)
Number of subjects: 60
Study: 31755989

Group type: EXPERIMENTAL
Intervention: Postoperative oral corticosteroids (OCS) in descending doses plus nasal douching over a period of 4 weeks
Number of subjects: 70

Group type: COMPARATOR
Intervention: Nasal douching only
Number of subjects: 70
Study: 31390037

Group type: EXPERIMENTAL
Intervention: TECH‐N intervention (text-messaging support and community health nurse visit within 5 days of diagnosis)
Number of subjects: 286

Group type: COMPARATOR
Intervention: Standard of care
Number of subjects: 286

Group type: EXPERIMENTAL
Intervention: TECH‐N intervention
Number of subjects: 286
Study: 27403926

Group type: EXPERIMENTAL
Intervention: Collaborative condition (n = 60)
Number of subjects: 120

Group type: COMPARATOR
Intervention: Individual condition (n = 60)
Number of subjects: 120

Group type: COMPARATOR
Intervention: Collaborative and individual conditions
Number of subjects: 120
Study: 25781537

Group type: EXPERIMENTAL
Intervention: Home-based strength training (HBST) for 16 weeks, twice weekly (n=15)
Number of subjects: 26

Group type: COMPARATOR
Intervention: Control group (C; n=15)
Number of subjects: 26
Study: 23348398

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Ketoconazole 400 mg
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Ketoconazole 800 mg
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Dutasteride 2.5 mg
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Anastrazole 1 mg
Number of subjects: 40
Study: 23193870

Group type: EXPERIMENTAL
Intervention: Rapid White
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Absolute White
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Speed White
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: White Glo
Number of subjects: 50

Group type: COMPARATOR
Intervention: Artificial Saliva (Control)
Number of subjects: 50
Study: 19567992

Group type: EXPERIMENTAL
Intervention: DHEA 50 mg daily
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study: 17033835

Group type: EXPERIMENTAL
Intervention: Balneotherapy (20-min bathing, once a day for five days per week for 3 weeks, total of 15 sessions)
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Balneotherapy (group 1)
Number of subjects: 24

Group type: COMPARATOR
Intervention: No intervention (group 2)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Healthy control group (group 3)
Number of subjects: 24
Study: 15309461

Group type: EXPERIMENTAL
Intervention: High n-6:n-3 PUFA diet (16)
Number of subjects: 29

Group type: COMPARATOR
Intervention: Moderate n-6:n-3 PUFA diet (9)
Number of subjects: 29
Study: 11304893

Group type: EXPERIMENTAL
Intervention: Low Dose (LD, 2 mg/kg)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Medium Dose (MD, 4.5 mg/kg)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: High Dose (HD, 7 mg/kg)
Number of subjects: 12
Study: 9151031

Group type: EXPERIMENTAL
Intervention: 43 microns heparin coated arterial line filter (Cobe Sentry)
Number of subjects: 40

Group type: COMPARATOR
Intervention: No filtration (control group)
Number of subjects: 40
Study: 7955265

Group type: EXPERIMENTAL
Intervention: Normothermic group (33.5 to 37 degrees C)
Number of subjects: 25

Group type: COMPARATOR
Intervention: Cold group (28 to 30 degrees C)
Number of subjects: 25
Study: 3672322

Group type: EXPERIMENTAL
Intervention: Intermittent sequential pneumatic compression alone
Number of subjects: 78

Group type: COMPARATOR
Intervention: Simultaneous use of graduated compression stockings and intermittent sequential pneumatic compression
Number of subjects: 78
Study: 29346507

Group type: EXPERIMENTAL
Intervention: Afatinib (14 days before surgery)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Control (no treatment)
Number of subjects: 30
Study: 28720032

Group type: EXPERIMENTAL
Intervention: EHR immunization alerts
Number of subjects: 264

Group type: COMPARATOR
Intervention: Control group (no EHR alerts)
Number of subjects: 264
Study: 25605643

Group type: EXPERIMENTAL
Intervention: Interval cycling followed by resistance exercise (ER)
Number of subjects: 8